Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227748 | 0.85 | PDK1 (0.46) | SIGMAR1TMEM97PREPKLK7PDK1 | |
| SCHEMBL3783660 | 0.82 | KLK7 (0.47) | SIGMAR1TMEM97PREPKLK7KLK5 | |
| SCHEMBL10144479 | 0.81 | PDK1 (0.46) | SIGMAR1TMEM97PREPPDK1PDK2 | |
| SCHEMBL15298942 | 0.75 | FKBP1A (0.51) | SIGMAR1TMEM97PREPPDK1PDK2 | |
| SCHEMBL6141635 | 0.75 | FKBP1A (0.51) | SIGMAR1TMEM97PREPPDK1PDK2 | |
| SCHEMBL6498226 | 0.75 | PRCP (0.52) | SIGMAR1TMEM97PREPFKBP1A | |
| SCHEMBL7499928 | 0.75 | PRCP (0.52) | SIGMAR1TMEM97PREPFKBP1A | |
| SCHEMBL27757433 | 0.74 | TMEM97 (0.52) | SIGMAR1TMEM97PREPPDK1PDK2 | |
| SCHEMBL27736650 | 0.74 | TMEM97 (0.52) | SIGMAR1TMEM97PREPPDK1PDK2 | |
| SCHEMBL13227741 | 0.73 | SIGMAR1 (0.53) | SIGMAR1TMEM97PREPPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | SIGMAR1 2777/4885TMEM97 4381/4885PREP 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.